Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Gregory Rasp who wrote (29458)	11/22/1999 7:47:00 PM
From: Andreas Helke	Read Replies (2) \| Respond to of 32384

Ligand is currently doing clinical trials of Targretin for breast cancer. If they are successful than Ligand might see substantial off label sales even before this indication gets approval. I am not sure if it is better to have a small market to oneself of compete in a big market like breast cancer with 50 to 100 other treatments that either already exist or are just now in development. Targretins combination of low toxicity with potentially substantial efficacy might earn it a substantial role even in a crowed field like breast cancer. But many me too drugs could end up with pretty limited sales. BTW CELG/ENMD's thalidomide has the big majority of its sales off label for cancer treatment. I doubt that Celgene would have bothered to get approval to treat leprosy symptoms with thalidomide if they had not counted on substantial off label sales. Andreas